Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. [electronic resource]
Producer: 20181119Description: 343-351 p. digitalISSN:- 1744-7682
- Blood Glucose -- analysis
- Body Weight
- Clinical Trials as Topic
- Diabetes Mellitus, Type 2 -- drug therapy
- Glucagon-Like Peptide-1 Receptor -- metabolism
- Glucagon-Like Peptides -- chemistry
- Glycated Hemoglobin -- analysis
- Humans
- Hypoglycemic Agents -- chemistry
- Injections, Subcutaneous
- Glucagon-Like Peptide-1 Receptor Agonists
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.